diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM12753diaendo-12753Research ArticleНовостиNewsРезолюция научно-консультативного совета «Применение технологии непрерывного мониторинга глюкозы с периодическим сканированием в достижении гликемического контроля»The Scientific Advisory board resolution: Implementation of intermittently scanned Continuous Glucose monitoring in clinical practice to improve glycemic controlhttps://orcid.org/0000-0002-5507-4627ПетерковаВ. А.PeterkovaV. A.

Петеркова Валентина Александровна - доктор медицинских наук, профессор, академик РАН; eLibrary SPIN: 4009-2463.

117036, Москва, ул. Дм. Ульянова, д. 11

Valentina A. Peterkova, MD, PhD, Professor; eLibrary SPIN: 4009-2463.

11 Dm. Ulyanova street, 117036 Moscow

peterkovava@hotmail.comhttps://orcid.org/0000-0002-7936-7619АметовА. С.AmetovA. S.

Аметов Александр Сергеевич - доктор медицинских наук, профессор.

Москва

Alexander S. Ametov, MD, PhD, Professor.

Moscow

alexander.ametov@gmail.comhttps://orcid.org/0000-0001-5825-3287МайоровА. Ю.MayorovA. Y.

Майоров Александр Юрьевич - доктор медицинских наук; eLibrary SPIN: 4275-7779.

Москва

Aleksander Y. Mayorov, MD, PhD; eLibrary SPIN: 4275-7779.

Moscow

education@endocrincentr.ruhttps://orcid.org/0000-0001-6581-4521ГалстянГ. Р.GalstyanG. R.

Галстян Гагик Радикович - доктор медицинских наук, профессор; eLibrary SPIN: 9815-7509.

Москва

Gagik R. Galstyan, MD, PhD, Professor; eLibrary SPIN: 9815-7509.

Moscow

galstyangagik964@gmail.comhttps://orcid.org/0000-0002-4316-8546ЛаптевД. Н.LaptevD. N.

Лаптев Дмитрий Никитич - доктор медицинских наук; eLibrary SPIN: 2419-4019.

Москва

Dmitry N. Laptev, MD, PhD; eLibrary SPIN: 2419-4019.

Moscow

laptevdn@ya.ruhttps://orcid.org/0000-0002-0562-8396ЧерниковаН. А.ChernikovaN. A.

Черникова Наталья Альбертовна - кандидат медицинских наук.

Москва

Natalya A. Chernikova, MD, PhD.

Moscow

nachendoc@yandex.ruНациональный медицинский исследовательский центр эндокринологииРоссияEndocrinology Research CentreRussian FederationРоссийская медицинская академия непрерывного профессионального образованияРоссияRussian Medical Academy of Continuous Professional EducationRussian Federation202114072021242185192Copyright © Петеркова В.А., Аметов А.С., Майоров А.Ю., Галстян Г.Р., Лаптев Д.Н., Черникова Н.А., 20212021Петеркова В.А., Аметов А.С., Майоров А.Ю., Галстян Г.Р., Лаптев Д.Н., Черникова Н.А.Peterkova V.A., Ametov A.S., Mayorov A.Y., Galstyan G.R., Laptev D.N., Chernikova N.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/12753

26 ноября 2020 г. состоялся Научно-консультативный совет под председательством академика РАН, профессора В.А. Петерковой, посвященный обсуждению возможности внедрения технологии непрерывного мониторинга глюкозы (НМГ) в клиническую практику врачей-эндокринологов в Российской Федерации с целью улучшения гликемического контроля у пациентов с сахарным диабетом (СД).

Основной задачей рабочей встречи было определение наиболее значимых с практической точки зрения показателей НМГ, необходимых для внедрения в клиническую практику, их характеристик для различных групп пациентов с СД.

В ходе мероприятия были обсуждены следующие темы и вопросы: важность выбора дополнительных критериев достижения гликемического контроля у пациентов с СД, помимо гликированного гемоглобина (HbA1c), место технологии НМГ в международных и российских клинических рекомендациях, точность систем НМГ и подходы к ее оценке, роль обучающих программ для пациентов с СД, в том числе обучения правильному использованию и интерпретации данных, получаемых при использовании устройств НМГ, анализ данных, полученных при изучении использования устройств НМГ в рандомизированных клинических исследованиях, а также данных, полученных в условиях повседневной клинической практики.

The Scientific Advisory Board chaired by Academician of the Russian Academy of Sciences, Peterkova V.A. was held 26 of November in Moscow to discuss the possibilities of continuous glucose monitoring technology (CGM) implementation into routine clinical practice in Russia in order to improve glycemic control in patients with diabetes mellitus (DM).

The main aims for Advisory board were to determine the most significant indicators and parameters for CGM to be implemented in practice from a practical point of view of LMWH, necessary for implementation in clinical practice, for different patients groups with diabetes.

The following questions and topics were raised within the discussion: the importance of additional indicators beyond glycated hemoglobin (HbA1c) for glycemic control assessment in diabetes patients, CGM positioning in International and Russian clinical guidelines, the accuracy of CGM devises and approaches to its assessment, the role of education programs for diabetic patients, including trainings in correct use and data interpretation and analysis of CGM data obtained, clinical evidence analysis for CGM in randomized trials and real world evidence.

гликированный гемоглобиннепрерывный мониторинг глюкозы с периодическим сканированиемвремя в целевом диапазонеflash-­мониторинг глюкозыglycated hemoglobinintermittently scanned continues glucose monitoringtime in rangeflash monitoringНаучно-консультативный совет экспертов, результаты которого легли в основу этой статьи, проводился при поддержке комании Abbott. Первый вариант рукописи также был поддержан компанией AbbottReferencesBattelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593-1603. doi: https://doi.org/10.2337/dci19-0028Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593-1603. doi: https://doi.org/10.2337/dci19-0028Monnier L, Colette C. Glycemic Variability: Should we and can we prevent it? Diabetes Care. 2008;31(2):S150-S154. doi: https://doi.org/10.2337/dc08-s241.Monnier L, Colette C. Glycemic Variability: Should we and can we prevent it? Diabetes Care. 2008;31(2):S150-S154. doi: https://doi.org/10.2337/dc08-s241.Rayman G. Glycaemic control, glucose variability and the Triangle of Diabetes Care. Br J Diabetes. 2016;16:3. doi: https://doi.org/10.15277/bjd.2016.070Rayman G. Glycaemic control, glucose variability and the Triangle of Diabetes Care. Br J Diabetes. 2016;16:3. doi: https://doi.org/10.15277/bjd.2016.070Аметов А.С., Черникова Н.А., Демидова Т.Ю. Вариабельность гликемии как терапевтическая мишень в лечении пациентов с сахарным диабетом 2 типа // Фарматека. — 2016. — №5. — С. 8-13.Ametov AS, Chernikova NA, Demidova TYu. Glycemic variability as a therapeutic target in the treatment of patients with type 2 diabetes mellitus. Farmateka. 2016;5:8-13. (In Russ.).Тиселько А.В., Ярмолинская М.И., Мишарина Е.В. Оценка вариабельности гликемического профиля как основа стратегии инсулинотерапии у беременных с сахарным диабетом 1 типа // Сахарный диабет. — 2019. — Т. 22. — №6. — С. 526-535. doi: https://doi.org/10.14341/DM10214Tiselko AV, Yarmolinskaya MI, Misharina EV. Evaluation of glycaemic profile variability as a basis for insulin therapy strategy in pregnant women with type 1 diabetes. Diabetes Mellitus. 2020;22(6):526-535. (In Russ.). doi: https://doi.org/10.14341/DM10214Лаптев Д.Н. Связь гипогликемии и вариабельности гликемии с автономной дисфункцией у детей и подростков с сахарным диабетом 1 типа // Сахарный диабет. — 2014. — Т. 17. — №4. — С. 87–92. doi: https://doi.org/10.14341/DM2014487-92Laptev DN. Relationship of hypoglycemia and glucose variability with autonomic dysfunction in children and adolescents with type 1 diabetes. Diabetes Mellitus. 2014;17(4):87-92. (In Russ.). doi: https://doi.org/10.14341/DM2014487-92Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care. 2019;42(3):400-405. doi: https://doi.org/10.2337/dc18-1444Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care. 2019;42(3):400-405. doi: https://doi.org/10.2337/dc18-1444Lu J, Ma X, Zhou J, et al. Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes. Diabetes Care. 2018;41(11):2370-2376. doi: https://doi.org/10.2337/dc18-1131Lu J, Ma X, Zhou J, et al. Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes. Diabetes Care. 2018;41(11):2370-2376. doi: https://doi.org/10.2337/dc18-1131Mayeda L, Katz R, Ahmad I, et al. Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease. BMJ Open Diabetes Res Care. 2020;8(1):e000991. doi: https://doi.org/10.1136/bmjdrc-2019-000991Mayeda L, Katz R, Ahmad I, et al. Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease. BMJ Open Diabetes Res Care. 2020;8(1):e000991. doi: https://doi.org/10.1136/bmjdrc-2019-000991Bergenstal R, Hachmann-Nielsen E, Kvist K. Derived time-in-range is associated with MACE in type 2 diabetes: data from the DEVOTE trial. Presented at EASD. 2020. Oral Presentation. 159 p.Bergenstal R, Hachmann-Nielsen E, Kvist K. Derived time-in-range is associated with MACE in type 2 diabetes: data from the DEVOTE trial. Presented at EASD. 2020. Oral Presentation. 159 p.Danne T, Nimri R, Battelino T, et al. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017;40(12):1631-1640. doi: https://doi.org/10.2337/dc17-1600Danne T, Nimri R, Battelino T, et al. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017;40(12):1631-1640. doi: https://doi.org/10.2337/dc17-1600Дедов И.И., Шестакова М.В., Майоров А.Ю. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом: Клинические рекомендации (Вып. 9) // Сахарный диабет. — 2019. — Т. 22. — №S1. — С. 1-144. doi: https://doi.org/10.14341/DM221S1Dedov II, Shestakova MV, Mayorov AYu, et al. Standards of specialized diabetes care. Diabetes Mellitus. 2019;22(S1):1-144 (In Russ.). doi: https://doi.org/10.14341/DM221S1DiMeglio LA, Acerini CL, Codner E, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. Pediatr Diabetes. 2018;19:105-114. doi: https://doi.org/10.1111/pedi.12737DiMeglio LA, Acerini CL, Codner E, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. Pediatr Diabetes. 2018;19:105-114. doi: https://doi.org/10.1111/pedi.12737Сахарный диабет 1 типа у взрослых. Клинические рекомендации // Сахарный диабет. — 2020. — Т. 23. — №S1. — С. 42-114. doi: https://doi.org/10.14341/DM20201SClinical guidlines. Diabetes mellitus type 1 in adults. Diabetes Mellitus. 2020;23(S1):42-114. (In Russ.). doi: https://doi.org/10.14341/DM20201SСахарный диабет 2 типа у взрослых. Клинические рекомендации // Сахарный диабет. — 2020. — Т. 23. — №S2. — С. 4-102. doi: https://doi.org/10.14341/DM20202SClinical guidlines. Diabetes mellitus type 2 in adults. Diabetes Mellitus. 2020;23(S2):4-102. (In Russ.). doi: https://doi.org/10.14341/DM20202SСахарный диабет 1 типа у детей. Клинические рекомендации. Сахарный диабет. — 2020. — Т. 23. — №S1. — С. 4-40. doi: https://doi.org/10.14341/DM20201SClinical guidlines. Diabetes mellitus type 1 in childhood. Diabetes mellitus type 1 in adults. Diabetes Mellitus. 2020;23(S1):4-40. (In Russ.). doi: https://doi.org/10.14341/DM20201SNational Institute for Health and Care Excellence (NICE). FreeStyle Libre for glucose monitoring (MIB110). 2017, July. P. 1–20.National Institute for Health and Care Excellence (NICE). FreeStyle Libre for glucose monitoring (MIB110). 2017, July. P. 1–20.Cardoso H, et al. Consenso Nacional para a Utilização do Sistema de Monitorização Flash da Glicose National Consensus on the Use of the Glucose Flash Monitoring System CONSENSO NACIONAL. Rev. Port. Diabetes. 2018;13(4):143-153.Cardoso H, et al. Consenso Nacional para a Utilização do Sistema de Monitorização Flash da Glicose National Consensus on the Use of the Glucose Flash Monitoring System CONSENSO NACIONAL. Rev. Port. Diabetes. 2018;13(4):143-153.Freckmann G, Schlüter S, Heinemann L. Replacement of Blood Glucose Measurements by Measurements With Systems for Real-Time Continuous Glucose Monitoring (rtCGM) or CGM With Intermittent Scanning (iscCGM): A German View. J Diabetes Sci Technol. 2017;11(4):653-656. doi: https://doi.org/10.1177/1932296817721004Freckmann G, Schlüter S, Heinemann L. Replacement of Blood Glucose Measurements by Measurements With Systems for Real-Time Continuous Glucose Monitoring (rtCGM) or CGM With Intermittent Scanning (iscCGM): A German View. J Diabetes Sci Technol. 2017;11(4):653-656. doi: https://doi.org/10.1177/1932296817721004Kudva YC, Ahmann AJ, Bergenstal RM, et al. Approach to Using Trend Arrows in the FreeStyle Libre Flash Glucose Monitoring Systems in Adults. J Endocr Soc. 2018;2(12):1320-1337. doi: https://doi.org/10.1210/js.2018-00294Kudva YC, Ahmann AJ, Bergenstal RM, et al. Approach to Using Trend Arrows in the FreeStyle Libre Flash Glucose Monitoring Systems in Adults. J Endocr Soc. 2018;2(12):1320-1337. doi: https://doi.org/10.1210/js.2018-00294Ajjan RA, Cummings MH, Jennings P, et al. Accuracy of flash glucose monitoring and continuous glucose monitoring technologies: Implications for clinical practice. Diabetes Vasc Dis Res. 2018;15(3):175-184. doi: https://doi.org/10.1177/1479164118756240Ajjan RA, Cummings MH, Jennings P, et al. Accuracy of flash glucose monitoring and continuous glucose monitoring technologies: Implications for clinical practice. Diabetes Vasc Dis Res. 2018;15(3):175-184. doi: https://doi.org/10.1177/1479164118756240Reiterer F, Polterauer P, Schoemaker M, et al. Significance and Reliability of MARD for the Accuracy of CGM Systems. J Diabetes Sci Technol. 2017;11(1):59-67. doi: https://doi.org/10.1177/1932296816662047Reiterer F, Polterauer P, Schoemaker M, et al. Significance and Reliability of MARD for the Accuracy of CGM Systems. J Diabetes Sci Technol. 2017;11(1):59-67. doi: https://doi.org/10.1177/1932296816662047Parkes JL, Slatin SL, Pardo S, Ginsberg BH. A new consensus error grid to evaluate the clinical significance of inaccuracies in the measurement of blood glucose. Diabetes Care. 2000;23(8):1143-1148. doi: https://doi.org/10.2337/diacare.23.8.1143Parkes JL, Slatin SL, Pardo S, Ginsberg BH. A new consensus error grid to evaluate the clinical significance of inaccuracies in the measurement of blood glucose. Diabetes Care. 2000;23(8):1143-1148. doi: https://doi.org/10.2337/diacare.23.8.1143Bailey T, Bode BW, Christiansen MP, et al. The Performance and Usability of a Factory-Calibrated Flash Glucose Monitoring System. Diabetes Technol Ther. 2015;17(11):787-794. doi: https://doi.org/10.1089/dia.2014.0378Bailey T, Bode BW, Christiansen MP, et al. The Performance and Usability of a Factory-Calibrated Flash Glucose Monitoring System. Diabetes Technol Ther. 2015;17(11):787-794. doi: https://doi.org/10.1089/dia.2014.0378Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kröger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388(10057):2254-2263. doi: https://doi.org/10.1016/S0140-6736(16)31535-5Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kröger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388(10057):2254-2263. doi: https://doi.org/10.1016/S0140-6736(16)31535-5Yaron M, Roitman E, Aharon-Hananel G, et al. Effect of Flash Glucose Monitoring Technology on Glycemic Control and Treatment Satisfaction in Patients With Type 2 Diabetes. Diabetes Care. 2019;42(7):1178-1184. doi: https://doi.org/10.2337/dc18-0166Yaron M, Roitman E, Aharon-Hananel G, et al. Effect of Flash Glucose Monitoring Technology on Glycemic Control and Treatment Satisfaction in Patients With Type 2 Diabetes. Diabetes Care. 2019;42(7):1178-1184. doi: https://doi.org/10.2337/dc18-0166Evans M, Welsh Z, Ells S, Seibold A. The Impact of Flash Glucose Monitoring on Glycaemic Control as Measured by HbA1c: A Meta-analysis of Clinical Trials and Real-World Observational Studies. Diabetes Ther. 2020;11(1):83-95. doi: https://doi.org/10.1007/s13300-019-00720-0Evans M, Welsh Z, Ells S, Seibold A. The Impact of Flash Glucose Monitoring on Glycaemic Control as Measured by HbA1c: A Meta-analysis of Clinical Trials and Real-World Observational Studies. Diabetes Ther. 2020;11(1):83-95. doi: https://doi.org/10.1007/s13300-019-00720-0Dunn TC, Xu Y, Hayter G, Ajjan RA. Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures: A European analysis of over 60 million glucose tests. Diabetes Res Clin Pract. 2018;137:37-46. doi: https://doi.org/10.1016/j.diabres.2017.12.015Dunn TC, Xu Y, Hayter G, Ajjan RA. Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures: A European analysis of over 60 million glucose tests. Diabetes Res Clin Pract. 2018;137:37-46. doi: https://doi.org/10.1016/j.diabres.2017.12.015Eeg-Olofsson K, Svensson A-M, Franzén S, et al. 74-LB: Sustainable HbA1c Decrease at 12 Months for Adults with Type 1 and Type 2 Diabetes Using the FreeStyle Libre System: A Study within the National Diabetes Register in Sweden. Diabetes. 2020;69(1):74-LB. doi: https://doi.org/10.2337/db20-74-LB.Eeg-Olofsson K, Svensson A-M, Franzén S, et al. 74-LB: Sustainable HbA1c Decrease at 12 Months for Adults with Type 1 and Type 2 Diabetes Using the FreeStyle Libre System: A Study within the National Diabetes Register in Sweden. Diabetes. 2020;69(1):74-LB. doi: https://doi.org/10.2337/db20-74-LB.Roussel R, Guerci B, Vicaut E, et al. 68-OR: Dramatic Drop in Ketoacidosis Rate after FreeStyle Libre System Initiation in Type 1 and Type 2 Diabetes in France, Especially in People with Low Self-Monitoring of Blood Glucose (SMBG): A Nationwide Study. Diabetes. 2020;69(1):68-OR. doi: https://doi.org/10.2337/db20-68-ORRoussel R, Guerci B, Vicaut E, et al. 68-OR: Dramatic Drop in Ketoacidosis Rate after FreeStyle Libre System Initiation in Type 1 and Type 2 Diabetes in France, Especially in People with Low Self-Monitoring of Blood Glucose (SMBG): A Nationwide Study. Diabetes. 2020;69(1):68-OR. doi: https://doi.org/10.2337/db20-68-ORCampbell FM, Murphy NP, Stewart C, et al. Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study. Pediatr Diabetes. 2018;19(7):1294-1301. doi: https://doi.org/10.1111/pedi.12735Campbell FM, Murphy NP, Stewart C, et al. Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study. Pediatr Diabetes. 2018;19(7):1294-1301. doi: https://doi.org/10.1111/pedi.12735Messaaoui A, Tenoutasse S, Crenier L. Flash Glucose Monitoring Accepted in Daily Life of Children and Adolescents with Type 1 Diabetes and Reduction of Severe Hypoglycemia in Real-Life Use. Diabetes Technol Ther. 2019;21(6):329-335. doi: https://doi.org/10.1089/dia.2018.0339Messaaoui A, Tenoutasse S, Crenier L. Flash Glucose Monitoring Accepted in Daily Life of Children and Adolescents with Type 1 Diabetes and Reduction of Severe Hypoglycemia in Real-Life Use. Diabetes Technol Ther. 2019;21(6):329-335. doi: https://doi.org/10.1089/dia.2018.0339

The authors declare that there are no conflicts of interest present.